Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.

Melanoma Res · 2024 · PMC10906191 · PMID 38181115

Europe PMC DOI

hedged sentence

0.0651

closest p · 1.3× alpha

0.0651

boldest claim

The sentences

an overall trendP = 0.0651so close (0.05 < p ≤ 0.1)

There was an overall trend in all stages toward a higher percentage of patients alive at last follow-up with combination ICI as compared with single-agent anti-PD-1 (74% versus 54%, P = 0.0651).

also in 909 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.